On Monday, Shares of Atlassian Corporation PLC (NASDAQ:TEAM), added 0.36% and closed at $27.59 in the last trading session. The last trading range of the stock ranges between $27.25 and $28.16. Atlassian Corporation Plc (TEAM), a leading provider of team collaboration and productivity software, today announced that senior management will present at the following investor conference:
UBS Global Technology Conference
Location: Ritz Carlton, San Francisco, CA
Date: Wednesday, November 16, 2016
Time: 9:30am PST (12:30pm EST)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), jumped 2.63% and closed at $94.42 in the last trading session. The last trading range of the stock ranges between $89.64 and $94.51. The company’s Market capitalization is $22.59 Billion with the total Outstanding Shares of 248.03 million. Vertex Pharmaceuticals Incorporated (VRTX) recently declared the results of a Phase 3 study of ORKAMBI® (lumacaftor/ivacaftor) in children with cystic fibrosis (CF) ages 6 through 11 who have two copies of the F508del mutation. The study met its primary endpoint of absolute change in lung clearance index (LCI2.5) through 24 weeks of treatment, demonstrating a statistically noteworthyimprovement in LCI2.5 among patients treated with ORKAMBI contrast to placebo. LCI is a sensitive measure of lung function in early CF disease and the European Medicines Agency (EMA) agreed to the primary endpoint for this study. In the first half of 2017, Vertex plans to submit a Marketing Authorization Application (MAA) line extension to the EMA for the use of ORKAMBI in this patient population. Data from a previous Phase 3 open-label safety study in children ages 6 through 11 supported the U.S. Food and Drug Administration approval of ORKAMBI in September 2016. In this second study, ORKAMBI was well tolerated with safety data that were similar to data from the previous Phase 3 study. There are about 3,400 children ages 6 through 11 who have two copies of the F508del mutation in Europe.